![]() |
|
|
Vol. 62, Issue 5, 975-982, November 2002
/Aryl Hydrocarbon Receptor Nuclear
Translocator DNA Binding by the 90-kDa Heat-Shock Protein Inhibitor
Radicicol
Department of Life Science, University of Seoul, Seoul, Korea (E.H., S.M.C., S.Y., Y.C., H.P.); Research Center for Proteineous Materials and School of Dentistry, Chosun University, Gwangju, Korea (H.-H.K.); Department of Bioscience and Biotechnology, Institute of Bioscience, Sejong University, Seoul, Korea (J.H.K., H.J.K., M.-O.L.); and Department of Environmental and Health Chemistry, College of Pharmacy, Chung-Ang University, Seoul, Korea (D.K.K.)
| |
Abstract |
|---|
|
|
|---|
Under low oxygen tension, cells increase the transcription of specific
genes involved in angiogenesis, erythropoiesis, and glycolysis.
Hypoxia-induced gene expression depends primarily on stabilization of
the
subunit of hypoxia-inducible factor-1 (HIF-1
), which acts as
a heterodimeric trans-activator with the nuclear protein
known as the aryl hydrocarbon receptor nuclear translocator (Arnt). The
resulting heterodimer (HIF-1
/Arnt) interacts specifically with the
hypoxia-responsive element (HRE), thereby increasing transcription of
the genes under HRE control. Our results indicate that the 90-kDa
heat-shock protein (Hsp90) inhibitor radicicol reduces the
hypoxia-induced expression of both endogenous vascular endothelial
growth factor (VEGF) and HRE-driven reporter plasmids. Radicicol
treatment (0.5 µg/ml) does not significantly change the stability of
the HIF-1
protein and does not inhibit the nuclear localization of
HIF-1
. However, this dose of radicicol significantly reduces HRE
binding by the HIF-1
/Arnt heterodimer. Our results, the first to
show that radicicol specifically inhibits the interaction between the
HIF-1
/Arnt heterodimer and HRE, suggest that Hsp90 modulates the
conformation of the HIF-1
/Arnt heterodimer, making it suitable for
interaction with HRE. Furthermore, we demonstrate that radicicol
reduces hypoxia-induced VEGF expression to decrease hypoxia-induced angiogenesis.
| |
Introduction |
|---|
|
|
|---|
Cells
adapt to hypoxia by up-regulating the transcription of specific genes
involved in angiogenesis, erythropoiesis, and glycolysis.
Pathologically, tumor hypoxia contributes directly to enhanced glucose
metabolism and angiogenesis, which are major features of malignant
progression. The genes up-regulated during hypoxia include vascular
endothelial growth factor (VEGF), erythropoietin, and several
glycolytic enzymes. These diverse, targeted genes are induced by a
common trans-activator, hypoxia-inducible factor 1 (HIF-1)
(Iyer et al., 1998
; Bruick and McKnight, 2001b
; Semenza, 2002
).
HIF-1 was first identified as a heterodimeric
trans-activator composed of two subunits, HIF-1
and -
,
both of which belong to the growing family of
basic-helix-loop-helix-PAS (bHLH-PAS) proteins, including period (Per),
Arnt, and single-minded (Sim). The bHLH-PAS proteins share common
characteristics: first, a bHLH-PAS protein dimerizes with a specific
partner protein through the HLH-PAS domain. Second, a partner such as
the aryl hydrocarbon receptor (AhR) or HIF-1
is activated by
specific stimuli (i.e., xenobiotics or low oxygen tension,
respectively) before translocating to the nucleus, where it
heterodimerizes with a partner protein. Alternatively, Arnt, another
bHLH-PAS protein, is constitutively located in the nucleus and
interacts with several bHLH-PAS proteins in diverse pathways. Arnt,
identical to HIF-1
, is known to be a common partner protein of AhR,
mouse Sim, and HIF-1
. Third, interactions between HLH-PAS domains
bring two basic regions of the two subunits into juxtaposition,
enabling individual basic regions to contact specific corresponding DNA
sequences. Thus, dimerization of bHLH-PAS proteins is a prerequisite
for DNA binding (Jiang et al., 1996
; Crews, 1998
; Taylor and Zhulin,
1999
). Arnt is capable of making a homodimer with a binding preference
for the palindromic E-box sequence (CACGTG), whereas neither AhR, mouse
Sim, nor HIF-1
makes a homodimer (Swanson et al., 1995
). The basic
region of Arnt contacts a half-site of E-box (GTG), whereas the other
partner protein determines the half-site specificity of the
corresponding DNA sequence that is different from E-box.
Analysis of AhR function led to the established paradigm for bHLH-PAS
protein function. A lipophilic inducer, such as dioxin, passively
diffuses into cells and binds to AhR, which is maintained in a
receptive configuration by the 90-kDa heat-shock protein (Hsp90).
Liganded AhR then separates from Hsp90 and appears in the nucleus,
where it heterodimerizes with Arnt, generating a functional
transcription factor that makes contact with the dioxin-responsive element. Antonsson et al. (1995)
demonstrated that at least two separate domains of AhR interact with Hsp90: the ligand-binding domain
within the PAS region and the bHLH domain. The PAS-Hsp90 interaction
corrects the conformation of the ligand-binding domain, whereas the
bHLH-Hsp90 interaction seems to be important for DNA-binding activity
but not for dimerization between AhR and Arnt. Association between the
AhR and cytosolic Hsp90 complex holds AhR in the cytosol in the absence
of ligand, thereby inhibiting dimerization between unliganded AhR and
the nuclear protein Arnt. Ligand binding to AhR triggers conformational
changes in AhR, which is followed by nuclear translocation and
dimerization with Arnt. Therefore, interaction with Hsp90 reduces
dimerization of unliganded AhR with Arnt and simultaneously induces the
conformation of AhR appropriate for both ligand binding and DNA
interaction. Thus, the dioxin receptor system provides a complex and
interesting model of the regulation of the bHLH-PAS transcription
factor by Hsp90 (Coumailleau et al., 1995
).
McGuire et al. (1995)
demonstrated that Sim is also stably associated
with Hsp90 and that dimerization with either Arnt or another PAS
protein, Per, efficiently disrupts the Sim-Hsp90 interaction. Several
studies have shown that Hsp90 interacts with HIF-1
and that the
Hsp90 inhibitor geldanamycin reduces the hypoxia-induced expression of
the HRE reporter gene, suggesting that Hsp90 regulates HIF-1
-dependent gene expression (Gradin et al., 1996
; Minet et al.,
1999
). AhR is primarily activated by the small lipophilic ligand
dioxin, whereas HIF-1
is primarily regulated by hypoxia-induced accumulation of the HIF-1
protein, which is otherwise rapidly degraded by the ubiquitin-proteasome pathway in normoxic cells (Kallio
et al., 1999
; Maxwell et al., 1999
). Recent studies have demonstrated that hydroxylation of the proline residue at position 564 of HIF-1
is catalyzed by proline hydroxylase in the presence of
molecular oxygen and iron. The tumor suppressor von Hippel-Lindau (VHL)
protein specifically interacts with hydroxylated HIF-1
and mediates
the assembly of a complex that activates the ubiquitin-E3 ligase.
Ubiquitinated HIF-1
is degraded by the proteasome. When cells are
hypoxic, the proline residue is not hydroxylated and HIF-1
protein
accumulates (Bruick and McKnight, 2001a
; Epstein et al., 2001
; Ivan et
al., 2001
; Jaakkola et al., 2001
). Although the activation processes of
AhR and HIF-1
are initiated by different mechanisms, they share many
functional properties. Specifically, both are associated with Hsp90 and
translocate to the nucleus upon stimulation and make heterodimers with
the same partner protein Arnt (Gradin et al., 1996
). Because results
from studies with AhR and MyoD suggest that interaction with Hsp90
corrects the conformation of the bHLH protein for DNA binding, we
expect that Hsp90 is also important for DNA-binding of the
HIF-1
/Arnt heterodimer (Shaknovich et al., 1992
; Antonsson et al.,
1995
).
Both radicicol and geldanamycin were first identified as transformation
suppressors of diverse oncogenes such as Src, Ras, and Mos.
Interestingly, the specific cellular target that binds radicicol is
Hsp90 which is not considered to be a signaling molecule (Kwon et al.,
1992
; Sharma et al., 1998
). Both radicicol and geldanamycin bind the
ATP-binding site of Hsp90 and block the assembly of Hsp90 heterocomplexes, including accessory cochaperone, p23, and immunophilin (Pratt, 1997
; Schulte et al., 1998
). These inhibitors, which do not
inhibit kinase activity, prevent Src-Hsp90 or Raf-1-Hsp90 heterocomplex
formation, thereby decreasing the stability and functionality of
signaling molecules. Immunoblotting analysis demonstrated that Raf-1,
p53, and p185erbB2 protein levels were substantially decreased by
treatment with radicicol and geldanamycin in SKBR3 cells, a breast
cancer cell line (Schulte et al., 1998
). Radicicol and geldanamycin
exhibit similar antiproliferative activities, probably because of
modulation of Hsp90; therefore, Hsp90 may become an important novel
target in anticancer drug development (Neckers et al., 1999
).
Here, we investigated whether radicicol inhibits the activation process
of HIF-1
in response to hypoxia. We dissected the HIF-1
activation process into several steps, including stabilization, nuclear
localization, DNA binding, and the start of transcription of
hypoxia-inducible VEGF. Our results demonstrate that radicicol specifically inhibits DNA binding of HIF-1
/Arnt, thereby reducing hypoxia-induced VEGF expression, which results in the reduction of
hypoxia-induced angiogenesis.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture and Hypoxia Treatment.
Hep 3B cells were
purchased from the American Type Culture Collection (Manassas, VA) and
cultured in MEM supplemented with 10% fetal bovine serum (FBS)
(Invitrogen, Gaithersburg, MD), 50 IU of penicillin, and 50 µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO) under humidified
air containing 5% CO2 at 37°C. Cells were
exposed to hypoxia (0.1% O2) by incubating cells
in an anaerobic incubator (model 1029; Forma Scientific, Marietta, OH)
in 5% CO2/10% H2/85%
N2 at 37°C. Hypoxia was also induced chemically
by treating cells with 100 µM CoCl2
(Sigma-Aldrich) (Mukhopadhyay et al., 1995
).
Inhibitors, Antibodies, and Plasmids.
Hep 3B cells were
treated with 150 µM of genistein (Sigma-Aldrich) in dimethyl
sulfoxide (DMSO), 10 µM PP2 (Calbiochem-Novabiochem Co., San Diego,
CA) in DMSO, 1 µg/ml geldanamycin (Sigma-Aldrich) in DMSO, and 0.5 µg/ml radiciol in DMSO. Radicicol was purified as described
previously (Kwon et al., 1992
). Anti-HIF-1
antibody and anti-Arnt
antibody were obtained from Transduction Laboratories (Lexington, KY).
The immunogen region for the anti-HIF-1
antibody is located between
amino acids 610 and 727. The p(HRE)4-luc reporter plasmid contains four copies of the hypoxia-responsive element (5'-GATCGCCCTACGTGCTGTCTCA-3') of erythropoietin (EPO), the simian virus 40 promoter, and the firefly luciferase gene (Ema et al., 1997
).
The p(EPO)-luc reporter plasmid contains one copy of the 3' enhancer of
EPO (nucleotides 3449-3470).
Preparation of Nuclear Extracts.
Hep 3B cells were serum
starved by incubation in MEM containing 0.5% FBS for 24 h and
then incubated in 0.1% O2 for 6 h. Nuclear extracts were prepared as described previously (Hur et al., 2001
). Confluent (70%) Hep 3B cells in 100-mm tissue culture plates were washed twice with ice-cold phosphate-buffered saline (PBS), resuspended in four packed cell volumes of buffer A (10 mM Tris-HCl, pH 7.8, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.4 mM
phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml
pepstatin, 2 µg/ml aprotinin, and 1 mM
Na3VO4) and incubated on
ice for 10 min. Subsequently, the cells were homogenized by 15 strokes
with a Dounce type-B pestle. The nuclei were pelleted by centrifugation
at 3,300g for 15 min at 4°C and resuspended in two packed
nuclei volumes of buffer B (20 mM Tris-HCl, pH 7.8, 1.5 mM
MgCl2, 450 mM KCl, 20% glycerol, 0.5 mM DTT, 0.4 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml
pepstatin, 2 µg/ml aprotinin, and 1 mM Na3VO4). The suspensions
were incubated with gentle rocking at 4°C for 1 h and
centrifuged at 25,000g for 30 min at 4°C. Supernatants were frozen at
80°C. Protein concentrations were measured by the
Bradford (1976)
assay.
Electrophoretic Mobility Shift Assay.
Oligonucleotides for
W18 (sense, 5'- agcttGCCCTACGTGCTGTCTCAg-3'; antisense,
5'-aattcTGAGACAGCACGTAGGGCa-3') were annealed and labeled (1.75 pmol)
with [
-32P]dATP and Klenow fragment.
Unincorporated nucleotides were removed by gel filtration over a
Sephadex G25 column. Nuclear extracts were preincubated with
poly(dI/dC) (500 ng) in 20 µl of buffer C (10 mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM MgCl2, 1 mM EDTA, 5 mM DTT, and
5% glycerol). The labeled W18 probe (5 × 105 cpm) was incubated with nuclear extract (10 µg) for 15 min at room temperature. The reactions were separated on a
5% polyacrylamide gel at 250 V in 0.5× Tris/borate/EDTA at 4°C.
Gels were vacuum-dried and autoradiographed. For supershift assays,
either anti-HIF-1
antibody or anti-Arnt antibody was added to the
reaction mixture and incubated for 2 h at 4°C before loading
(Semenza and Wang, 1992
).
Western Analysis of HIF-1
and Coimmunoprecipitation.
Hep
3B cells were serum-starved by incubation in MEM containing 0.5% FBS
for 40 to 48 h before treatment with inhibitors or hypoxia. Cells
were washed once with ice-cold PBS and lysed in radioimmunoprecipitation assay buffer containing 150 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.4, 100 µg/ml phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml
aprotinin, 50 mM
-glycerophosphate, 25 mM NaF, 20 mM EGTA, 1 mM DTT,
and 1 mM Na3VO4. The
lysates were centrifuged at 10,000g for 10 min at 4°C. The
protein concentrations of the supernatants were measured by the
Bradford (1976)
assay. An equal amount of each protein sample (30 µg)
was used and Western analysis was performed as described previously
(Hur et al., 2001
). Nuclear extracts (250 µg) were prepared as
described above and precleared by incubating with 1 µg of anti-mouse
IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and 20 µl of
0.5% ImmunoPure immobilized protein A/G gel (Pierce, Rockford, IL) for
10 min at 4°C. The cleared extracts were mixed with 2 µg of
anti-Arnt antibody. After addition of 20 µl of 0.5% ImmunoPure
immobilized protein A/G gel, mixtures were rotated for 4 h at
4°C and centrifuged. Immunoprecipitated pellets were washed three
times in buffer and then resuspended in SDS sample buffer. The entire
samples were boiled for 3 to 5 min before electrophoresis through an
8% SDS-polyacrylamide gel. The proteins were transferred onto
nitrocellulose membrane by semidry transfer (Trans-Blot SD; Bio-Rad,
Hercules, CA). Coimmunoprecipitated proteins were immunoblotted with
either anti-HIF-1
antibody or anti-Arnt antibody. HIF-1
or Arnt
proteins were visualized using enhanced chemiluminescence according to
the manufacturer's instructions (Amersham Biosciences, Piscataway, NJ)
with an anti-mouse Ig conjugated with horseradish peroxidase as a
secondary antibody.
Northern Analysis.
Hep 3B cells were grown to 80%
confluence on 100-mm tissue culture plates. Total RNA was isolated
using an RNeasy spin column according to the manufacturer's
instructions (QIAGEN, Chatsworth, CA). Total RNA (12 µg) was
electrophoresed through a 1% agarose gel containing formaldehyde and
transferred to nitrocellulose membrane. Blots were hybridized with
-32P-labeled cDNA of VEGF, phosphoglycerate
kinase-1 (PGK-1), or actin, washed, dried, and autoradiographed with
Hyperfilm MP (Amersham Biosciences). The expression levels of VEGF,
PGK-1 and actin were measured with a radioisotope imaging
analyzer (Bas2000; Fuji, Tokyo, Japan).
Transient Transfection and Luciferase Assay.
Hep 3B cells
were plated at 1 × 105 cells per well in a
12-well plate. Eighteen hours later, transfection was carried out using Superfect reagent (QIAGEN) according to the manufacturer's
instructions. Twelve hours before hypoxic treatment, transfected Hep 3B
cells were serum starved with medium containing 0.5% FBS. Forty-eight hours after transfection, cell extracts were prepared and analyzed with
a luminometer (Berthold Lumat LB9501) using the luciferase assay system
(Promega, Madison, WI). Each measured luciferase activity was
normalized for total protein concentration, as measured by the Bradford
(1976)
assay using bovine serum albumin as a standard. The transfection
efficiency was monitored by measuring cotransfection of the
-galactosidase encoding plasmid (pCHO110) and
-galactosidase activity.
Fluorescence Microscopy.
Hep 3B cells were cultured on a
cover-slide and treated with the control vehicle (DMSO) or radicicol
(0.5 µg/ml) at 30 min before the 4 h exposure to
CoCl2 (75 µM). Cells were washed twice with PBS
and fixed with 3.7% paraformaldehyde, permeabilized with 0.1% Triton
X-100. Cells were then incubated for 1 h at 20°C with anti-HIF-
antibody diluted to 1:100 in PBS containing 3% FBS and
1% bovine serum albumin. After washing twice with PBS, cells were
incubated for 30 min at 20°C with fluorescein isothiocyanate-coupled secondary anti-mouse antibody staining (1:100 dilution). Cells were
washed twice with PBS and incubated with 500 mM propidium iodide for 5 min at 20°C. Nuclei were visualized by staining propidium iodide.
After washing three times with PBS, stained cells and nuclei were
observed with fluorescence microscope.
Capillary Tube Formation Assay.
The bovine fibroblast growth
factor (bFGF) was obtained from Upstate Biotechnology (Lake Placid,
NY), the Matrigel from Collaborative Biomedical Products (Bedford, MA),
and Microcon YM-10 from Millipore (Bedford, MA). The early passages
(5-7 passages) of bovine aortic endothelial cells (BAECs) were kindly
provided by Dr. I. Jo at the National Institutes of Health of
Korea. BAECs were grown in MEM supplemented with 10% FBS at 37°C in
a humidified atmosphere of 5% CO2. Hep 3B cells
were treated with geldanamycin (1 µg/ml in DMSO) or radicicol (0.1, 0.5 or 2.5 µg/ml in DMSO) 1 h before a 16-h exposure to 0.1%
O2. The cell medium was prepared from treated Hep
3B cells in low serum medium (0.5% FBS). Each cell medium was filtered
through Microcon YM-10 to filter out low molecular mass
materials of less than 10 kDa. Agent removal was confirmed by
thin-layer chromatography of the ethyl acetate extract from the
Microcon YM-10 concentrated cell medium. To conduct the capillary tube
formation assay, 250 µl of matrigel (10 mg/ml) was placed in a
24-well culture plate and polymerized for 30 min at 37°C. The BAECs
(1 × 105 cells) were seeded on the surface
of the Matrigel and treated with bFGF (30 ng/ml). Then 50 µl of
concentrated cell medium was added to each sample and incubated for
18 h. The morphological changes in the cells and tubes were
observed under a microscope and photographed at × 100 magnification using a JVC digital camera (TK-C1380U; JVC,
Yokohama, Japan) (Kim et al., 2001
).
| |
Results |
|---|
|
|
|---|
The Hsp90 Inhibitor Radicicol Represses Hypoxia-Induced Gene
Expression.
To investigate the possibility that Hsp90 modulates
hypoxia-induced gene expression, we first measured the changes in
hypoxia-induced expression of both endogenous genes and HRE-driven
reporter genes in Hep 3B cells that had been pretreated with several
inhibitors. For the following analyses, we serum-starved Hep 3B cells
before hypoxic stimulation because serum itself slightly activates the function of HIF-1
under normoxic conditions and thereby reduces the
hypoxia-inducibility of HIF-1
activity (D'Angelo et al., 2000
;
Richard et al., 2000
). Then, several inhibitors were added to the cell
medium of Hep 3B cells 1 h before hypoxic exposure. We exposed
cells to hypoxic conditions by incubating cells in a hypoxic chamber
(0.1% O2) or treating cells with the
hypoxia-mimicking agent, CoCl2. Treatment with
radicicol (0.5 µg/ml, 1.4 µM) partially reduces hypoxia-induced
expression of the endogenous VEGF and PGK-1
genes, as shown in Fig. 1A. We also found
that geldanamycin (1 µg/ml, 1.8 µM), another Hsp90 inhibitor,
reduces hypoxia-induced VEGF and PGK-1
expression. Treatment with the tyrosine kinase inhibitor genistein (150 µM) and the Src specific inhibitor PP2 (10 µM) also reduces
hypoxia-induced expression of endogenous VEGF and
PGK-1 as shown in Fig. 1A. We used two hypoxia-inducible reporter plasmids containing either four copies of HRE or 50 base pairs
of the EPO 3' enhancer region upstream of the simian virus 40 promoter
and luciferase gene (Huang et al., 1996
). Treatment with radicicol
decreased the hypoxia-induced expression of both reporter genes dose
dependently (Fig. 1B).
|
directly or indirectly through tyrosine kinase
action (Bijlmaker and Marsh, 2000Effects of Radicicol on Hypoxia-Induced Stabilization of
HIF-1
.
The activation process of HIF-1
is initiated by the
hypoxia-induced stabilization of the HIF-1
protein. Hsp90 acts as a chaperone to protect cells from nonnative proteins, which increase in
response to heat shock and other stresses. Thus, we sought to
investigate whether Hsp90 is involved in the accumulation of HIF-1
upon hypoxic stress. We measured the changes in HIF-1
protein levels
in Hep 3B cells that were treated with inhibitors before hypoxic
exposure. Western analyses displayed multiple bands that were
recognized by anti-HIF-1
antibody, indicating that stabilized
HIF-1
undergoes strong post-translational modifications (Fig.
2A). In hypoxic cells, slowly migrating
HIF-1
is more stable than fast-migrating HIF-1
. Although
treatment with radicicol slightly reduces the stability of slowly
migrating HIF-1
by 23%, it increases the stability of the fast
migrating one by 35%. Overall, treatment with radicicol (0.5 µg/ml)
decreases the total amount of hypoxia-induced HIF-1
protein by 5%
(Fig. 2A). However, an equivalent dose of radicicol reduces
hypoxia-induced gene expression of both reporter and endogenous genes
(Fig. 1). In contrast, treatment with the tyrosine kinase inhibitors
genistein or PP2 significantly reduced the total amount of stabilized
HIF-1
protein. When hypoxic conditions were mimicked by
CoCl2 treatment, similar results were observed
(Fig. 2B).
|
, suggesting that
radicicol-induced reduction of hypoxia-induced gene expression is not
caused by decreased tyrosine kinase activity. The question, then, is
how does radicicol reduce hypoxia-induced activation of HIF-1
?
Effects of Radicicol on Nuclear Localization of HIF-1
.
Release of Hsp90 is critical for unmasking functional activities such
as nuclear localization, dimerization, and DNA binding of the AhR and
glucocorticoid receptor. Because the partner protein Arnt
constitutively locates in the nucleus, dimerization between Arnt and
cytosolic HIF-1
requires nuclear translocation of HIF-1
(Shaknovich et al., 1992
; Pratt, 1997
). Kallio et al. (1998)
demonstrated that hypoxia-inducible nuclear accumulation of HIF-1
depends on a nuclear localization signal within the C-terminal region of HIF-1
. Nuclear translocation of many trans-activators
is conditionally stimulated by signal-induced conformational changes
and the unmasking of nuclear localization signals. To test whether
hypoxia-induced nuclear localization of HIF-1
is modulated by
radicicol, we visualized HIF-1
proteins in radicicol treated cells
by immunofluorescence. Our results indicate that upon hypoxic exposure,
the HIF-1
protein is exclusively detected in the nucleus, whereas
HIF-1
is not visible in normoxic cells (shown in Fig.
3). Treatment with radicicol did not
change either the amount of HIF-1
protein or the hypoxia-induced nuclear localization of HIF-1
. This observation using fluorescence microscopy is consistent with the finding that radicicol does not
change the hypoxia-induced stability of HIF-1
(Fig. 2). Our finding
suggests that the Hsp90 inhibitor radicicol does not block nuclear
localization of HIF-1
to reduce hypoxia-induced gene expression.
|
Effects of Radicicol on the Hypoxia-Induced DNA Binding Ability of
the HIF-1 Complex.
To test whether radicicol affects the
protein-protein interaction between HIF-1
and Arnt, we treated Hep
3B cells with radicicol before exposure to hypoxia and then prepared
nuclear protein extracts. Immuno-precipitation was performed using
anti-Arnt antibody and coprecipitated HIF-1
was detected by Western
analysis using anti-HIF-1
antibody. Our results indicate that
treatment with radicicol does not reduce the interaction between Arnt
and HIF-1
in hypoxic cells. To investigate the effect of radicicol
on the ability of the HIF-1
/Arnt complex to bind HRE in response to
hypoxia, the nuclear extracts were mixed with a radiolabeled
oligonucleotide (W18) that contains the HRE sequence and the mixture
was subjected to the electrophoretic mobility shift assay (EMSA)
(Semenza and Wang, 1992
). As observed in previous EMSAs with HRE, our
results revealed the presence of hypoxia-induced, constitutive and
nonspecific complexes (Hur et al., 2001
). The hypoxia-induced complex
was detected only when nuclear extracts from hypoxic Hep 3B cells were
assayed. To examine the composition of the hypoxia-induced complexes,
nuclear extracts were mixed with either anti-HIF-1
antibody or
anti-Arnt antibody and were then subjected to EMSA. Supershifts
confirmed the presence of HIF-1
and Arnt in the complex (Fig.
4B). Treatment with radicicol
significantly reduced the hypoxia-induced DNA binding of the HIF-1
complex, indicating that Hsp90 does affect the DNA binding of the
HIF-1
/Arnt heterodimer (Fig. 4B). As shown in Figs. 2 and 3,
radicicol does not change hypoxia-induced stability, nuclear
localization of HIF-1
, or the protein interaction between Arnt and
HIF-1
, although it specifically reduces the DNA binding ability of
the HIF-1 complex. We speculated that the Hsp90 inhibitor radicicol
restrains the proper conformation of the bHLH domains of HIF-1,
resulting in the loss of DNA binding activity of the HIF-1 heterodimer,
thereby reducing hypoxia-induced gene expression.
|
The Effect of Radicicol-Treated Cell Medium on Capillary Tube
Formation of Endothelial Cells.
To verify that radicicol actually
reduces the secretion of VEGF from hypoxic cells, which may affect
angiogenesis, we tested the effect of radicicol treated cell medium
from Hep 3B cells on capillary tube formation in bovine aortic
endothelial cells (BAECs). Capillary tube formation is a key phenotype
of angiogenesis induced by VEGF (Kim et al., 2001
). We removed
radicicol or geldanamycin from the cell medium by filtering out low
molecular mass materials of less than 10 kDa and confirmed the absence
of radicicol or geldanamycin in the cell medium by thin-layer
chromatography of an ethyl acetate extract from the cell medium. As
shown in Fig. 5, cultured BAECs on the
Matrigel formed an extensive network of thick tubes in the presence of
bovine fibroblast growth factor (bFGF). Hypoxia-treated cell medium
increased tube formation as much as the positive control treated with
bFGF, suggesting the expression of VEGF in hypoxic Hep 3B cells (Fig.
5, A to C). However, geldanamycin (1 µg/ml) or radicicol treated
hypoxic cell medium displayed reduced tube formation in BAECs in a
dose-dependent manner compared with the untreated hypoxic cell medium
(Fig. 5, D to G). The staining of cell medium-treated BAECs with trypan blue confirmed that the reduction in tube formation was not caused by
cytotoxic effects (data not shown). Accordingly, these results demonstrate that radicicol reduces the secretion of the angiogenic factor VEGF from hypoxic cells.
|
| |
Discussion |
|---|
|
|
|---|
We investigated the modulatory effects of the Hsp90 inhibitor
radicicol on the HIF-1 activation process in response to hypoxia. We
dissected the HIF-1 activation process into several steps, including
stabilization of the HIF-1
protein, nuclear translocation, heterodimerization with Arnt, DNA binding of the HIF-1
/Arnt complex, and the ultimate expression of both hypoxia-inducible endogenous and
reporter genes. We found that hypoxia-induced DNA binding of HIF-1
is more sensitive to inhibition by radicicol than is the stability of
the HIF-1
protein. Reduced gene expression of VEGF and PGK-1 results
from the hypoxia-induced inhibition of HIF-1
DNA binding. Our
results suggest that Hsp90 regulates the DNA binding step of the
HIF-1
activation process. The addition of recombinant or purified
Hsp90 to EMSAs has been shown to increase the DNA binding ability of
the bHLH protein MyoD. This activation process involves a transient
interaction between Hsp90 and MyoD that does not involve the formation
of a stable tertiary complex such as DNA-MyoD-Hsp90 (Shaknovich et al.,
1992
). The results suggest that transient interaction of DNA-binding
proteins with Hsp90 can affect their DNA binding activity.
Richard et al. (1999)
demonstrated that phosphatase treatment of
hypoxic cell extracts removed slowly migrating HIF-1
, but not
fast-migrating proteins, indicating that hypoxia-induced
phosphorylational modification of HIF-1
slows electrophoretic
migration. In hypoxic cells, the slowly migrating HIF-1
is more
stable than the fast-migrating HIF-1
. Our results show that
radicicol decreases the proportion of slowly migrating HIF-1
to
fast-migrating HIF-1
(Fig. 2). Further investigation is needed to
determine whether these proportional changes affect the function of
HIF-1
or Hsp90.
Recently, HIF-1
was also recognized as a novel, tumor-specific
target for anticancer therapy because 1) it is an essential transcription activator of VEGF and many glycolytic enzymes, which are
required for angiogenesis and continued tumor growth; 2) it is present
only in hypoxic cells, which are common inside solid tumors (Brown,
2000
). Hsp90 inhibitors result in the destabilization and degradation
of Hsp90 client proteins, including mutated p53, Raf-1, and ErbB2.
Furthermore, Hsp90 inhibitors have already exhibited promising
antitumor activity such as antiproliferative and antiangiogenic effects
(Oikawa et al., 1993
; Neckers et al., 1999
). Another Hsp90 inhibitor,
the oxime derivative of radicicol known as KF58333 (1 µM), decreased
the HIF-1
protein level under both normoxia and hypoxia in human
breast cancer cells in vitro and inhibited growth and angiogenesis in
human breast cancer xenografts (Kurebayashi et al., 2001
). Therefore,
Hsp90 inhibitors could become useful as hypoxia-sensitive and
therapeutic antiangiogenic and antitumor agents.
The subcellular distribution of Hsp90 in hypoxic cells is not well
understood. Minet et al. (1999)
demonstrated that Hsp90 does not
cotranslocalize with HIF-1
into the nucleus upon hypoxia in COS-7
cells. In contrast, Katschinski et al. (2002)
showed that hypoxia does
not increase the total amount of Hsp90 and induces nuclear
translocation of Hsp90 in HepG2 cells. Our immunofluorescence studies
demonstrated that the concentration and subcellular distribution of
Hsp90 in Hep 3B cells are not significantly changed by
CoCl2 treatment (data not shown). Although the
subcellular localization of Hsp90 in hypoxic cells is not clear,
coimmunoprecipitation analyses showed that Hsp90 interacts with the
bHLH-PAS domain of HIF-1
in normoxia but not in hypoxia (Gradin et
al., 1996
; Minet et al., 1999
). However, the effects of the interaction
between HIF-1
and Hsp90 on the functions of HIF-1
, such as DNA
binding and transcriptional activation of target genes in hypoxic
cells, must be investigated in the future.
| |
Footnotes |
|---|
Received March 22, 2002; Accepted July 23, 2002
This study was supported by a grant from the 1999 Korean National Cancer Control Program, Ministry of Health and Welfare and Grant 1999-1-209-003-3 from the Korean Science and Engineering Foundation (to H.P.). H.-H.K. was supported by the National Research Laboratory grant from the Ministry of Science and Technology and the Engineering Research Center grant from the Korean Science and Engineering Foundation. H.J.K. was supported by a research grant of Korea Science and Engineering Foundation.
Address correspondence to: Dr. Hyunsung Park, Department of Life Science, University of Seoul, 90 Cheonnong-dong, Tongdaemun-gu, Seoul 130-743, Korea. E-mail: hspark{at}uoscc.uos.ac.kr
| |
Abbreviations |
|---|
VEGF, vascular endothelial growth factor; HIF-1, hypoxia-inducible factor-1; bHLH, basic helix loop helix; Arnt, aryl hydrocarbon receptor nuclear translocator; Per, period; Sim, single-minded; AhR, aryl hydrocarbon receptor; PAS, period/aryl hydrocarbon receptor/single minded; Hsp90, 90-kDa heat-shock protein; HRE, hypoxia responsive element; VHL, von Hippel-Lindau; MEM, minimal essential medium; FBS, fetal bovine serum; DMSO, dimethyl sulfoxide; PP2, 4-amino-5-(4-chlorophenyl)-7-(t-tubyl)pyrazolo[3,4-d]pyrimidine; EPO, erythropoietin; PBS, phosphate-buffered saline; DTT, dithiothreitol; EMSA, electrophoretic mobility shift assay; PGK-1, phosphoglycerate kinase 1; BAEC, bovine aortic endothelial cell; bFGF, bovine fibroblast growth factor.
| |
References |
|---|
|
|
|---|
-subunit.
J Biol Chem
271:
32253-32259
Targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
Science (Wash DC)
292:
464-468
to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Science (Wash DC)
292:
468-472
EMBO (Eur Mol Biol Organ) J 17:6573-6586.
by the ubiquitin-proteasome pathway.
J Biol Chem
274:
6519-6525
is dependent on heat shock protein-90 activity.
J Biol Chem
277:
9262-9267
(HIF-1
) and enhance the transcriptional activity of HIF-1*.
J Biol Chem
274:
32631-32637This article has been cited by other articles:
![]() |
O. A. Toogun, D. C. DeZwaan, and B. C. Freeman The Hsp90 Molecular Chaperone Modulates Multiple Telomerase Activities Mol. Cell. Biol., January 1, 2008; 28(1): 457 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schmitt, M. Gehrmann, M. Brunet, G. Multhoff, and C. Garrido Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy J. Leukoc. Biol., January 1, 2007; 81(1): 15 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Linehan, J. Vasselli, R. Srinivasan, M. M. Walther, M. Merino, P. Choyke, C. Vocke, L. Schmidt, J. S. Isaacs, G. Glenn, et al. Genetic Basis of Cancer of the Kidney: Disease-Specific Approaches to Therapy Clin. Cancer Res., September 15, 2004; 10(18): 6282S - 6289S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Powis and L. Kirkpatrick Hypoxia inducible factor-1{alpha} as a cancer drug target Mol. Cancer Ther., May 1, 2004; 3(5): 647 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-C. Teng, Y.-Y. Chen, Y.-N. Su, P.-C. Chou, Y.-C. Chiang, S.-F. Tseng, and K.-J. Wu Direct Activation of HSP90A Transcription by c-Myc Contributes to c-Myc-induced Transformation J. Biol. Chem., April 9, 2004; 279(15): 14649 - 14655. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, T. Schmid, R. Frank, and B. Brune PI3K/Akt Is Required for Heat Shock Proteins to Protect Hypoxia-inducible Factor 1{alpha} from pVHL-independent Degradation J. Biol. Chem., April 2, 2004; 279(14): 13506 - 13513. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hopfl, O. Ogunshola, and M. Gassmann HIFs and tumors--causes and consequences Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C Chi and J. S Karliner Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors Cardiovasc Res, February 15, 2004; 61(3): 437 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-x. Chen, M. L. Lawrence, G. Cunningham, B. W. Christman, and B. Meyrick HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium J Appl Physiol, February 1, 2004; 96(2): 612 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Tschan, K. M. Fischer, V. S. Fung, F. Pirnia, M. M. Borner, M. F. Fey, A. Tobler, and B. E. Torbett Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns J. Biol. Chem., October 31, 2003; 278(44): 42750 - 42760. [Abstract] [Full Text] [PDF] |
||||